World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
38890
World Ranking
11590
National Ranking
1102

Gerhardt Attard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gerhardt Attard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 412 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gerhardt Attard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gerhardt Attard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gerhardt Attard is affiliated with University College London in the United Kingdom. Their research work primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with notable contributions in subfields such as Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging, Oncology, and Molecular Biology.

The scientist's main areas of study encompass several topics related to cancer and its treatment, including:

  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Genomics and Diagnostics
  • Cancer, Lipids, and Metabolism
  • PARP inhibition in cancer therapy
  • Cancer Immunotherapy and Biomarkers

Attard has collaborated frequently with several co-authors, including:

  • Nicholas D. James
  • Noel W. Clarke
  • Silke Gillessen
  • Matthew R. Sydes
  • Felix Y. Feng

Their work has been published in a variety of journals, with notable frequent venues including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • Cancer Research
  • European Urology Oncology

Among recent papers authored by the scientist are:

  • "ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group", 2022, Annals of Oncology
  • "The Lancet Commission on prostate cancer: planning for the surge in cases", 2024, The Lancet
  • "Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019", 2020, European Urology
  • "Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer", 2023, Journal of Clinical Oncology
  • "Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial", 2023, Annals of Oncology

Best Publications

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

    Joaquin Mateo;Suzanne Carreira;Shahneen Sandhu;Susana Miranda

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud

  • Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

    Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker

  • Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

    G Attard;J Clark;L Ambroisine;G Fisher

  • Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

    Alison H.M. Reid;Gerhardt Attard;Daniel C. Danila;Nikhil Babu Oommen

  • Erratum: Integrative Clinical Genomics of Advanced Prostate Cancer

    Dan Robinson;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Plasma AR and abiraterone-resistant prostate cancer.

    Alessandro Romanel;Delila Gasi Tandefelt;Vincenza Conteduca;Anuradha Jayaram;Anuradha Jayaram

  • Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Y. Loriot;D. Bianchini;E. Ileana;S. Sandhu

  • Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

    Howard I Scher;Glenn Heller;Arturo Molina;Gerhardt Attard

  • Tumor clone dynamics in lethal prostate cancer

    Suzanne Carreira;Alessandro Romanel;Jane Goodall;Emily Grist;Emily Grist

  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

    S Gillessen;A Omlin;G Attard;J S de Bono

  • Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

    N.W. Clarke;A. Ali;F.C. Ingleby;A. Hoyle

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

    Silke Gillessen;Gerhardt Attard;Tomasz M. Beer;Himisha Beltran

  • Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

    Gerhardt Attard;Gerhardt Attard;Alison H. M. Reid;Alison H. M. Reid;Richard J. Auchus;Beverly A. Hughes

Frequent Co-Authors

Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Chris Parker
Chris Parker Institute of Cancer Research
David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Nicholas D. James
Nicholas D. James Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Colin Cooper
Colin Cooper University of East Anglia
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Matthew R. Sydes
Matthew R. Sydes University College London
Francesca Demichelis
Francesca Demichelis University of Trento
Malcolm David Mason
Malcolm David Mason Cardiff University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens doors not only through traditional MD programs but also through a variety of online healthcare degrees. Many students start their journey by looking at entry-level options like medical billing and coding cost to get hands-on administrative experience in the medical field. This can provide valuable insights and skills for those considering a future in healthcare.

For students interested in direct patient care, becoming a nurse is a popular path. You can find some of the cheapest online BSN programs that allow you to study flexibly around your schedule, making it easier to balance work and education. If you’re ready to advance your nursing career, there are pathways such as the cheapest FNP programs (Family Nurse Practitioner) which offer advanced clinical roles and greater responsibilities.

For those aiming for leadership or academic positions, pursuing a doctorate can be a smart move. Online options like doctorate in nursing education online programs offer specialized training for nurse educators and researchers, expanding your opportunities in the healthcare field.

Best Scientists Citing Gerhardt Attard

Trending Scientists

Recently Published Articles